FDA finalizes guidance aligning biosimilar post-approval manufacturing changes with global standards

The U.S. Food and Drug Administration has issued its final guidance on how biosimilar manufacturers can implement post-approval changes to their production processes.

The new recommendations bring U.S. expectations into line with international guidelines, giving companies clearer pathways to modify manufacturing without restarting the approval process.

For the first time, the guidance also addresses changes to interchangeable biosimilars, a category that was not covered in earlier FDA documents.